Studies with transgenic mice are beginning to define the minimal requirements for the somatic hypermutation of immunoglobulin genes that is critical in the production of high-affinity antibodies.
One of the hallmarks of an advanced vertebrate immune system is the ability of the body to remember an invading organism, and to educate itself to respond more vigorously upon a second 'antigenic' challenge by the same organism. After first contact with an antigen, a portion of the responding B cells migrate to the germinal centers of lymphoid organs, where they undergo a fantastic evolution. The B cells hypermutate their rearranged immunoglobulin variable genes and undergo a process of natural selection, whereby the clones that produce antibodies with the highest affinity survive while other clones die [1] . This results in 'memory' B cells, which have 102 to 10 3 times higher affinity for the cognate antigen than do the cells in the original clone. In two weeks, this breathtaking process creates a million years' worth of mutation and selection in a somatic recapitulation of evolution. Over the last decade, our knowledge of this process has grown considerably, although often the results may seem confusing or contradictory. The published data are like pieces of a dauntingly complex biological puzzle; only recently have a few pieces, here and there, begun to fit together to give us a view of the molecular mechanism driving hypermutation.
We now know that the hypermutation occurs only at the 5' end of immunoglobulin genes, centering on the rearranged variable (V), diversity (D) and joining J) gene segments. The mutations appear to be randomly distributed over a 2 kb region with a well-defined 5' end, starting in the promoter region, and an amorphous 3' end trailing into the intron downstream of the V(D)J coding region [2] . Work from several laboratories [3] [4] [5] [6] [7] has linked the immunoglobulin-gene mutation frequency with the presence of both the intronic transcriptional 'enhancer' element between the V(D)J and constant (C) regions and the 3' enhancer downstream of the C region (Fig. 1 ). This suggests that mutation correlates with an 'open' DNA structure, associated with the potential for transcription. There is, however, no evidence directly connecting hypermutation to the transcription rate. Furthermore, hypermutation appears to occur only in germinal-center B cells [8] , which express low levels of immunoglobulin mRNA and cytoplasmic immunoglobulin [9, 10] . The role of the enhancers and transcription may therefore be merely permissive, opening the gene to make it accessible to the hypermutation machinery.
This leaves unanswered the question of the cis DNA sequences which target the hypermutation machinery to the 5' end of the rearranged immunoglobulin gene. While the epicenter of mutation is the V(D)J region, the targeted area is skewed downstream into the V/C intron, and trails off after about 1 000 bases. At the 5' end, mutations end much more abruptly, in that they occur over a 300 bp region and are not usually found upstream of the promoter. Although evidence from several laboratories has suggested that the promoter and/or the rearranged V(D)J gene are involved in targeting the mutation mechanism, recent experiments by Neuberger, Milstein, and their colleagues [11, 12] indicate that neither the V7 gene nor the immunoglobulin gene promoter are required for hypermutation.
Last year, Betz et al. [11] reported that, whereas the intronic enhancer and the 3' enhancer were specifically needed to produce somatic hypermutation of a K light Fig. 1 . Transgene constructs used to investigate the cis DNA sequence requirements for somatic hypermutation. The first four constructs were made by Betz et al. [11] : the first is similar to the endogenous rearranged K chain locus; the second and third are deletion constructs, with either the 3' or intronic enhancer (E) removed. In the fourth construct, the K promoter (P) has been replaced with the P-globin promoter (13P chain transgene, the immunoglobulin gene promoter was not. They removed the K promoter, the transcription start site and the 5' nontranslated region, and replaced it with the corresponding section of the P-globin gene promoter (Fig. 1) . Although the modified transgene had one-third fewer mutations compared with the original construct, it was still able to undergo hypermutation. Taken together with previous results, this again suggests that the transcriptional state of the gene is important for hypermutation.
Yelamos et al. [12] have recently added yet another piece to the hypermutation puzzle. Using the same K construct as Betz et al. [11] , they removed the VJ coding region of the transgene and replaced it with similar-size inserts of the bacterial neo gene, the bacterial gpt gene or the human P-globin gene (Fig. 1) . In a step which wisely conserved both time and money, they constructed a transgenic mouse that contained not only the neo and the gpt variant constructs, but also a previously-tested K transgene as a positive control for hypermutation. In a second line of mice, they inserted the human 1-globin gene alone.
The transgene sequences for analysis of hypermutation were amplified, using the polymerase chain reaction (PCR), either directly from germinal-center B cells from Peyer's patches -lymphoid follicles on the small intestine -or from hybridomas. The first approach allowed for the rapid recovery and analysis of many transgenes; and the second permitted a more detailed analysis of the three different transgenes coexisting in the same cell. The two approaches gave the same results. The VJ coding region could be replaced, even by a bacterial gene, without disrupting hypermutation of the normally targeted area. Thus there is nothing unique about the coding region of the variable gene that targets hypermutation to it.
Analysis of the mutations indicated that, as is typical of somatic hypermutation, most were single-base substitutions, with a bias towards transitions over transversions. Also, in support of these same authors' earlier theory [11] , there appear to be several mutation hotspots in the gpt and -globin transgenes. These hotspots center around a triplet that is either AGC or AGT, both of which, in frame, code for a serine residue. Such hotspots suggest that the mutation mechanism may recognize local DNA structure in the coding region [13] . Hotspots have not, however, been found in the heavily mutated 5' and 3' nontranslated regions flanking the V(D)J gene [2, 14] . This suggests that, while AGC/T may be a highly susceptible substrate for mutation, recognition of a substrate by the hypermutation machinery requires more than a simple sequence motif. Strand discrimination, where the four bases are not mutated equally on both strands, was also observed on the -globin and neo-substituted transgenes, although the exact pattern varied from that seen in V(D)J genes. The target sequence must therefore play a role in determining the type of mutation.
As clear as these results seem, not every sequence placed downstream of an immunoglobulin gene promoter will necessarily undergo hypermutation. At the Ninth International Congress on Immunology in July, there were three independent reports of results differing from those of Yelamos et al. [12] . Ursula Storb's group (University of Chicago) placed a second immunoglobulin promoter just upstream of the C coding region, and observed six-fold lower mutation in the area. Tim Manser's group (Thomas Jefferson University) substituted the CD72 gene for the VJ coding region, and did not find hypermutation of the transgenes in hybridomas from transgenic mice. Finally, our group placed 2 kb of bacteriophage DNA downstream of the promoter in a K transgene, and did not detect hypermutation of the X DNA sequence. Clearly, these results muddy the waters. The results of Yelamos et al. [12] nevertheless add an exciting piece to the puzzle of hypermutation, and may help fit a few more of the pieces together. We can now begin to close in on the cis DNA sequences that target hypermutation with such exquisite specificity, and start to hunt in earnest for the molecular machinery that creates these extraordinary mutations.
